Study shows direct relationship between Alzheimer s tau protein and Cholesterol

60.00% credibility
 
Related

A mom wrote a heartwarming letter to Hillary Clinton about her dreams for her daughter s future

Atma
640 points

Woman Can't Decide Which Dogs To Save So She Buys The Entire Shelter

Atma
528 points



Most recent

M del Val: A finales de marzo se producirá una ola muy fuerte, muchas personas mayores morirán

Henri Monzó Catalá
82 points

Bill Gates, el cambio climático y el coronavirus

Henri Monzó Catalá
14 points

BARRANQUILLA ABRE SU PRIMERA PELUQUERÍA DE LUJO BAJO UN CONCEPTO DE GALERÍA DE ARTE Y BELLEZA

Tecnologia
6 points

Solo cambió de vida, murió

Enrique TF
14 points

Tips de mantenimiento de calderas y calentadores

Mis Noticia
8 points

¿Qué debemos reciclar en los Puntos SIGRE de las farmacias?

Henri Monzó Catalá
28 points

Volver a vivir

Enrique TF
10 points

Consejos para una alimentación sana

Ruben Galiza
18 points

¿Tomar el sol a través de una ventana sirve para sintetizar la vitamina D?

Henri Monzó Catalá
10 points

Se nos fue el tiempo

Enrique TF
8 points
SHARE
TWEET
We have known for some years that Alzheimer’s disease is characterised by two types of lesions, amyloid plaques and degenerated tau protein. Cholesterol plays an important role in the physiopathology of this disease. Two French research teams (Inserm/CEA/University of Lille/University of Paris-Sud ) have just shown, in a rodent model, that overexpressing an enzyme that can eliminate excess cholesterol from the brain may have a beneficial action on the tau component of the disease, and completely correct it. This is the first time that a direct relationship has been shown between the tau component of Alzheimer’s disease and cholesterol. This work is published in the 10 September 2015 issue of Human Molecular Genetics.

Study shows direct relationship between Alzheimer   s tau protein and Cholesterol

xcess brain cholesterol cannot freely cross the blood-brain barrier; to be eliminated it must be converted into 24-hydroxycholesterol (24-OHC) by the enzyme CYP46A1 (cholesterol-24-hydroxylase). At Inserm Unit 1169, Nathalie, Cartier, coordinator of this work, and Patrick Aubourg, director of the unit, proposed the hypothesis that increasing the efflux of cholesterol from the brain by overexpressing CYP46A1 might have a beneficial effect on the elements of Alzheimer pathology.

The first step in this work made it possible to show that injecting a viral vector, AAV-CYP46A1, effectively corrects a mouse model of amyloid pathology of the disease, the APP23 mouse. CYP46A1 thus appears to be a therapeutic target for Alzheimer’s disease.

Conversely, in vivo inhibition of CYP46A1 in the mice, using antisense RNA molecules delivered by an AAV vector administered to the hippocampus, induces an increase in the production of Aß peptides, abnormal tau protein, neuronal death and hippocampal atrophy, leading to memory problems. Together these elements reproduce a phenotype mimicking Alzheimer’s disease.

These results demonstrate the key role of cholesterol in the disease, and confirm the relevance of CYP46A1 as a potential therapeutic target (work published in Brain on 3 July 2015).

Taken together, this work now enables the research team coordinated by Nathalie Cartier, Inserm Research Director, to propose a gene therapy approach for Alzheimer’s disease: intracerebral administration of a vector, AAV-CYP46A1, in patients with early and severe forms (1% of patients, familial forms) for whom there is no available treatment.

“To achieve this objective, we are carrying out all the preclinical steps of development and validation of the tools (vector, neurosurgical protocol, elements of monitoring) for demonstrating the efficacy and tolerance of the strategy, in order to submit an application for authorisation of a clinical trial,” explains Nathalie Cartier.

Fuente: neurosciencenews.com
SHARE
TWEET
To comment you must log in with your account or sign up!
Featured content